We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Biosearch Technologies Selected for SBIR Grants Issued by the DoD for Disease Detection
News

Biosearch Technologies Selected for SBIR Grants Issued by the DoD for Disease Detection

Biosearch Technologies Selected for SBIR Grants Issued by the DoD for Disease Detection
News

Biosearch Technologies Selected for SBIR Grants Issued by the DoD for Disease Detection

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Biosearch Technologies Selected for SBIR Grants Issued by the DoD for Disease Detection"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Biosearch Technologies, Inc. (Biosearch) has announced that the company has been selected for two Small Business Innovative Research (SBIR) grants from the Department of Defense (DoD).

The purpose of both Phase I grants is to develop sensitive analyte specific reagents (ASRs) for a total of twelve pathogens of military importance. The ASRs will be based on real time quantitative Polymerase Chain Reaction (qPCR) modified for field deployment in overseas military operations.

The first grant includes six viral target pathogens (Dengue, Rift Valley Fever, Sand Fly Fever, Crimean-Congo Hemorrhagic Fever, Tick-Borne Encephalitis, and Chikungunya), while the second includes six Rickettsial pathogens (the causative agents of typhus, spotted fever, anaplasmosis, Ehrlichioses, and Q fever). Many of these agents are listed as Category A or B Priority Pathogens by the National Institute of Allergy and Infectious Diseases (NIAID). Successful completion of Phase I is expected to lead to a multiyear Phase II award.

Jerry Ruth, PhD, is the Director of Research and Development at Biosearch, and the Principal Investigator of the Award. Dr Ruth comments, “Reagents for the rapid and specific detection of highly infectious and often lethal diseases in the field of operations are of paramount importance in saving the lives of military personnel. Additionally, such reagents are also the key to identifying the source and limiting the spread of such pathogens.”
Advertisement